**Name of Journal: *World Journal of Clinical Oncology***

**ESPS Manuscript NO: 26745**

**Manuscript Type: Review**

**Oncogenic fingerprint of epidermal growth factor receptor pathway and emerging epidermal growth factor receptor blockade resistance in colorectal cancer**

Sobani ZA *et al.* EGFR pathway and EGFR blockade resistance

**Zain A Sobani, Ashwin Sawant, Mikram Jafri, Amit Keith Correa, Ibrahim Halil Sahin**

**Zain A Sobani,** Department of Medicine, Maimonides Medical Center, New York, NY 11219, United States

**Ashwin Sawant, Amit Keith Correa, Ibrahim Halil Sahin,** Department of Medicine, Icahn School of Medicine at Mount Sinai St Luke’s Roosevelt Hospital Center, New York, NY 10019, United States

**Mikram Jafri,** Department of Medicine, Albany Stratton Veterans Hospital, Albany, New York, NY 12208, United States

**Author contributions:** All authors contributed to this manuscript.

**Conflict-of-interest** **statement:** All authors have no financial or non-financial conflict of interest including but not limited to commercial, personal, political, intellectual, or religious interests related to this manuscript.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Invited manuscript

**Correspondence to:** **Ibrahim Halil Sahin, MD,** Department of Medicine, Icahn School of Medicine at Mount Sinai St Luke’s Roosevelt Hospital Center, 1000 10th Avenue, New York, NY 10019, United States. md.ibrahim.halil.sahin@gmail.com

**Telephone:** +1-212-5234000

**Received:** April 25, 2016

**Peer-review started:** April 26, 2016

**First decision:** June 16, 2016

**Revised:** July 18, 2016

**Accepted:** August 6, 2016

**Article in press:**

**Published online:**

**Abstract**

Epidermal growth factor receptor (EGFR) has been an attractive target for treatment of epithelial cancers, including colorectal cancer (CRC). Evidence from clinical trials indicates that cetuximab and panitumumab (anti-EGFR monoclonal antibodies) have clinical activity in patients with metastatic CRC. The discovery of intrinsic EGFR blockade resistance in Kirsten RAS (*KRAS*)-mutant patients led to the restriction of anti-EFGR antibodies to KRAS wild-type patients by Food and Drug Administration and European Medicine Agency. Studies have since focused on the evaluation of biomarkers to identify appropriate patient populations that may benefit from EGFR blockade. Accumulating evidence suggests that patients with mutations in EGFR downstream signaling pathways including KRAS, BRAF, PIK3CA and PTEN could be intrinsically resistant to EGFR blockade. Recent whole genome studies also suggest that dynamic alterations in signaling pathways downstream of EGFR leads to distinct oncogenic signatures and subclones which might have some impact on emerging resistance in *KRAS* wild-type patients. While anti-EGFR monoclonal antibodies have a clear potential in the management of a subset of patients with metastatic CRC, further studies are warranted to uncover exact mechanisms related to acquired resistance to EGFR blockade.

**Key words:** Epidermal growth factor receptor; Oncogenic signature; *KRAS*; *BRAF*; Cetuximab; Panitumumab; Epidermal growth factor receptor blockade resistance

**© The Author(s) 2016.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Epidermal growth factor receptor (EGFR) blockade treatment is a well-established targeted therapy in metastatic colorectal cancer (CRC) patients. However, a limited number of patients benefit from EGFR inhibition, with limited time duration of response. This review article discusses the most recent updates from the current-state-of-the-science related to molecular pathways of EGFR signaling, the mechanism of action and efficacy of EGFR blockade treatment, and possible molecular pathways related to EGFR blockade resistance in CRC. We further discuss potential mechanisms contributing to targeted EGFR inhibition. Lastly, future perspectives are discussed to shed some light on efforts to overcome this potential challenge in the era of targeted treatment.

Sobani ZA, Sawant A, Jafri M, Correa AK, Sahin IH. Oncogenic fingerprint of epidermal growth factor receptor pathway and emerging epidermal growth factor receptor blockade resistance in colorectal cancer. *World J Clin Oncol* 2016; In press

**INTRODUCTION**

Colorectal cancer (CRC) with an incidence of 1.2 million cases per year is now the third most common cancer in males and second in females[[1](#_ENREF_1)]. Although there is a minor trend to decrease in the incidence of the disease, it is yet one of the major health care burden in United States[[2](#_ENREF_2)]. Despite extensive research, limited number targeted agents have been shown to be active in CRC.

Cetuximab and Panitumumab are two new generation monoclonal antibodies targeting epidermal growth factor receptor (EGFR) recently approved by the Food and Drug Administration (FDA) for the management of metastatic CRC in the United States. Although their exact mechanism of action is unknown it is hypothesized that the direct interaction of these antibodies with EGFR results in apoptosis. Herein, we discuss the molecular signature of the EGFR pathway, the possible mechanism of action of anti-EGFR monoclonal antibodies, the clinical consequences of these cell-based interactions in treatment of metastatic CRC, along with emerging resistance to these agents during the treatment of CRC.

**ONCOGENIC SIGNATURE OF EGFR PATHWAYS IN CRC**

EGFR, also known as ErbB, is a member of a receptor tyrosine kinase family; it stimulates multiple intracellular proto-oncogenic signaling mediators including Kirsten RAS (*KRAS*)[[3](#_ENREF_3)]. As a 170 kDa transmembrane glycoprotein expressed on cell surface, EGFR has physiological roles in many organs including the epithelium of the gastrointestinal system, bronchial tract and cutaneous tissue[[4](#_ENREF_4)]. In normal homeostasis, EGFR is activated by binding with external ligands such as growth factors [epidermal growth factor (EGF), epiregulin or amphiregulin]. This interaction initiates homodimerization and heterodimerization processes *via* a diverse combination of identical and different members of the family such as ErbB2 (HER 2), ErbB3 (HER 3) and ErbB4 (HER 4)[[5](#_ENREF_5)]. The ensuing phosphorylation of tyrosine kinase domain results in activation of oncogenic pathways including mitogen activated protein kinase (MAPK) and phosphotidylinositol-3-kinase (PI3KCA) pathways (Figure 1). These signaling axes have been shown to function in many critical pro-survival cellular reactions in cancer cells including protein synthesis, cell growth, cell cycle progression, transformation and invasion. KRAS, a critical growth signal response in cancer cells, is an upstream activator of the MAPK pathway[[6](#_ENREF_6)] (Figure 1). KRAS-driven MAPK translocates into the cell nucleus, initiates a transcription cascade and promotes cell growth[[7](#_ENREF_7)] For example, KRAS activation leads to upregulation of c-myc which fuels proliferation of human colon cancer cells and provides a survival advantage[[8](#_ENREF_8)]. Signal cascades of KRAS also induce cell cycle progression *via* activation of the transcription factor Elk-1, which ultimately increases the expression of cell cycle promoting proteins such Cyclin D1[[9](#_ENREF_9)]. Moreover, as a part of the complex network of EGFR signaling, the KRAS driven MAPK pathway interacts with JNK signaling to modulate cellular stress responses which enhance cellular plasticity. This response helps malignant cells to adapt to dynamic microenvironmental changes[[10](#_ENREF_10)]. In transformed cancer cells, *KRAS* mutations abolish regulation *via* the upstream EGFR loop; the MAPK and PI3KCA pathways, and other pro-survival cascades are continuously activated, leading to distinct cellular behavior[[11](#_ENREF_11),[12](#_ENREF_12)].

Phosphatidylinositol 3-kinase (PIK3CA) is another well-studied signal transducer of the EGFR pathway. In normal homeostasis, activation of PIK3CA by EGFR leads to induction of Akt-mTOR pathway which has been shown to be crucial signal for protein synthesis and cell cycle progression[[13](#_ENREF_13)]. Activation of PIK3CA also abrogates apoptosis and cellular senescence in cancer cells[[14](#_ENREF_14)]. PIK3CA-driven mTOR activates Bcl-2 and ultimately inhibits apoptosis[[15](#_ENREF_15)], indicating that PIK3CA signaling may have an important role in the immortality of transformed cells. PIK3CA activation has also been shown to be related to elevated expression of COX-2 which enhances angiogenesis in CRC[[16](#_ENREF_16)]. Consistent with evidence from preclinical observations, mutant *PIK3CA* is associated with development of various cancers including CRC[[17](#_ENREF_17)]. Current thinking suggests that the changes in the gene expression profile caused by activating mutations of PIK3CA may culminate in changes in the proteome of cancer cells and that this transformation enhances cellular growth and invasion by creating distinct oncogenic signatures[[18](#_ENREF_18)].

BRAF, a member of the RAF kinase family, functions as a serine/threonine protein kinase, and gets activated by the upstream Ras oncogene (Figure 1)[[19](#_ENREF_19)]. Activating mutations of the BRAF oncogene occur in the kinase domain and the V599E mutation accounts for the vast majority of point mutations (approximately 80%)[[20](#_ENREF_20)]. Mutant *BRAF* propagates Raf-MAPK signaling in the absence of upstream stimulation and ultimately induces cell growth and proliferation in malignant clones[[21](#_ENREF_21)]. Similar to *PIK3CA* mutations, *BRAF* mutations also transform the protein expression profiles of cancer cells and alter internal metabolism. For example, CRC cells with mutant *BRAF* were found to be more resistant to apoptosis compared to those carrying wild-type BRAF[[22](#_ENREF_22)]. Moreover, *BRAF* may increase the expression of cell cycle promoting proteins which further enhance the expansion of selected clones[[23](#_ENREF_23)]. *BRAF* mutations have also been shown to be associated with constitutively activated NF-κB[[24](#_ENREF_24)], leading to tumor angiogenesis that optimizes the microenviroment for cancer cells[[24](#_ENREF_24)]. All this evidence suggests that activation of the BRAF oncogene may add further distinct characteristics to the cancer cells’ genomic fingerprint.

*Src* and *STAT*, two other critical oncogenes, have been demonstrated to be involved in the development and progression of epithelial tumors along with cancer angiogenesis, and both mediators operate in the signaling cascade of the EGFR pathway[[25](#_ENREF_25)]. A study showed that EGFR overexpressing cancer cells bear a 10-fold increase in Src activity compared to low EGFR expressing cancer cells[[26](#_ENREF_26)], and that increased Src activity has been associated with highly aggressive tumor behavior and metastatic potential in CRC cells[[27](#_ENREF_27)]. Oncogenic Src, as a non-receptor tyrosine kinase (nRTK), turns on many downstream survival pathways such Ras-MAPK pathway. It further activates receptor tyrosine kinases which create continuous growth signals for cancer cells[[28](#_ENREF_28)]. Activating mutations of *Src* are related to adverse outcomes in CRC[[29](#_ENREF_29),[30](#_ENREF_30)]. STATs are also activated by EGFR[[25](#_ENREF_25)] and function as transcriptional factors in downstream pathways of receptor tyrosine kinases and cytokine receptors[[31](#_ENREF_31)]. Induction of STATs through EGFR signaling[[32](#_ENREF_32)] may also fuel angiogenesis in the tumor microenvironment[[33](#_ENREF_33)]. Although activation of STATs has shown to be related to enhanced proliferation in CRC cancer cells[[34](#_ENREF_34)], the exact role of STATs in development and progression of CRC remains to be elucidated.

Altogether, current evidence indicates intricate EGFR signaling. Variant alterations in the downstream signal transducers of EGFR are likely responsible for the change in expression profiles and molecular behavior of cancer cells.

**EMERGENCE OF MONOCLONAL CHIMERIC ANTIBODIES TO EGFR**

Considering the diverse oncogenic pathways activated by EGFR, it has become a promising target for therapy in various epithelial tumors[[35](#_ENREF_35),[36](#_ENREF_36)]. The aforementioned studies led to research targeting EGFR signaling *via* different approaches, including small molecule inhibitors of receptor tyrosine kinases such as erlotinib and monoclonal antibodies to neutralize the receptor *via* an internalization and degradation process.

The initial investigations in this field were conducted using murine anti-EGFR antibodies. In these studies, both agonist and antagonist antibodies were tested[[37](#_ENREF_37)], and antagonist antibodies inhibited the proliferation of the malignant clones with high affinity binding[[38](#_ENREF_38)]. Since murine antibodies are recognized as foreign antigens in humans, human-mouse chimeric antibodies were generated to further study this effect and they were shown to have superior biological efficacy compared to murine antibodies in human tumor xenograft models[[39](#_ENREF_39)]. Cetuximab, a chimeric antibody against EGFR, was demonstrated to have 10 times higher affinity to EGFR compared the murine antibodies (M225)[[40](#_ENREF_40)], and limited toxicity was observed in phase I clinical studies[[41](#_ENREF_41)].

The mechanism of action of anti-EGFR antibodies was at first attributed to internalization of receptors bound by the anti-EGFR antibodies[[42](#_ENREF_42)]. Further studies demonstrated that the EGFR blockading agents not only catalyze the removal of the receptors but also inhibit receptor tyrosine kinase activity, and induce apoptosis *via* cell cycle arrest in colonic adenocarcinoma cell lines[[43](#_ENREF_43)]. Besides its-single agent activity, an enhanced anti-cancer effect of cetuximab was observed in combination with the topoisomerase inhibitor (irinotecan) in human CRC xenograft models[[44](#_ENREF_44)]. These discoveries led to further studies to elucidate the role of EGFR blockade in modern cancer treatment, and clinical trials were opened for enrollment in different clinical settings.

**CLINICAL TRIALS TO ASSESS THE ROLE OF EGFR BLOCKADE IN CRC TREATMENT**

To further investigate the promising results observed in preclinical studies, early phase and clinical efficacy trials were designed (Table 1). A phase I safety trial was conducted to determine the optimal biological dose, and the doses achieved at maximal systemic clearance were well tolerated in both monotherapy and combined treatment models[[45](#_ENREF_45)]. In a phase II clinical trial of 120 irinotecan-resistant CRC patients with positive EGFR expression, cetuximab reversed the resistance to irinotecan with a 22.5% major objective response rate and 17% radiologic response rate in a combination treatment model[[46](#_ENREF_46)]. The promising radiological response rate had already resulted in FDA approval for the cetuximab treatment for metastatic CRC patients. In order to solidify the response observed in the original study, cetuximab was investigated as a single agent treatment in patients with advanced stage refractory CRC[[47](#_ENREF_47)]. In this study, 9% partial response rate along with a median survival of 6.4 mo was reported after cetuximab monotherapy in CRC patients expressing EGFR. To further investigate these findings and to test the superiority of combination treatment to monotherapy, a randomized phase II clinical trial was conducted[[48](#_ENREF_48)]. Patients were randomized to receive cetuximab and irinotecan combination *vs* cetuximab alone. Patients in the combination arm demonstrated a 22.9% partial response compared to 10.8% in the cetuximab monotherapy arm (*P* = 0.007). While progression free survival (PFS) was significantly improved in patients receiving combination therapy there was no overall survival (OS) difference between the groups. A subsequent study demonstrated limited survival benefit in patients treated with cetuximab compared to best supportive care (6.1 mo *vs* 4.6 mo respectively)[[49](#_ENREF_49)]. Although EGFR expression was considered as a predictor of EGFR blockade response in early clinical trials, this concept has since changed and EGFR expression is no longer considered a biomarker in CRC patients[[50](#_ENREF_50)].

The observed improvement in response rate in the treatment of irinotecan-refractory cases led to further studies in treatment-naïve patients. The CRYSTAL study showed significantly improved PFS in metastatic CRC patients who received a cetuximab plus FOLFIRI (bolus 5-fluoruracil/leucovorin chemotherapy plus irinotecan) regimen compared to patients who underwent FOLFIRI treatment alone (Table 1). However, there was no significant difference in OS between the two groups[[51](#_ENREF_51)]. Subsequent analysis of the study demonstrated improved OS (approximately 3.5 mo) in patients with wild-type KRAS who underwent cetuximab treatment. No significant response was observed in *KRAS*-mutant patients[[52](#_ENREF_52)]. This study led to the FDA approval of cetixumab as a first line treatment in combination with FOLFIRI in patients with metastatic CRC. In the OPUS study, cetuximab was combined with FOLFOX-4 and an improved PFS [hazard ratio (HR) 0.567, *P* = 0.0064] was observed in KRAS wild-type metastatic CRC patients who received combination therapy[[53](#_ENREF_53)]. In order to assess the role of cetuximab in earlier stages of the disease, N0137 trial was conducted: Stage III CRC patients were enrolled to receive cetuximab plus FOLFOX-6 combinations *vs* FOLFOX-6 in adjuvant settings after initial resection[[54](#_ENREF_54)]. After a of median 28 mo follow up in both wild-type and mutant *KRAS* groups, results of this trial showed no benefit of cetuximab when added to FOLFOX-6 regimen in the setting of locally advance disease. In order to compare the efficacy of cetuximab in combinations with FOLFOX-6 and FOLFIRI regimens as a neoadjuvant treatment in unresectable metastatic CRC patients, a phase II clinical trial (CELIM trial) was conducted[[55](#_ENREF_55)]. Although there was no significant survival difference between the two groups, addition of cetuximab resulted in higher response rates compared to historical controls (FOLFOX and FOLFIRI). A total 36 of 116 patients were able to receive R0 resection. The result of this study was also consistent with previous studies demonstrating improved outcomes limited to patients with wild type KRAS.

Panitumumab, another monoclonal antibody for EGFR blockade, has also been investigated in CRC patients. This agent received FDA approval after prolonged PFS was demonstrated in an open-label phase III clinical trial in which patients were enrolled to receive single-agent panitumamab *vs* best supportive care (median PFS, 8 wk *vs* 7.3 wk; HR, 0.54; 95%CIL 0.44-0.66)[[56](#_ENREF_56)]. Follow up analysis of this study showed that the survival benefit was again, limited to wild-type KRAS CRC patients[[57](#_ENREF_57)]. A retrospective study suggested potential resistance in patients with BRAF V600E mutation and requirement of wild-type BRAF for clinical benefit, along with wild-type KRAS[[58](#_ENREF_58)]. Currently this drug is also approved as a first line agent in combination with FOLFOX4 in metastatic CRC patients with wild-type KRAS due to observed improvement in PFS in a randomized phase III clinical trial (PRIME trial; median PFS, 9.6 mo vs 8.0 mo; P = 0.02)[[59](#_ENREF_59)]. A small phase II trial evaluated Panitumumab in 33 wild-type KRAS metastatic CRC patients whom were deemed ineligible for chemotherapy. The study demonstrated a PFS rate of 36.4%, objective response rate of 9.1% and stable disease in 54.5% of patients. The median PFS was 4.3 mo and OS was 7.1 mo, indicating a role for Panitumumab monotherapy in patients who are not eligible for chemotherapy[[60](#_ENREF_60)].

**EMERGING RESISTANCE TO EGFR BLOCKADE**

The promising results observed with monoclonal antibodies either as monotherapy or in combination treatments in metastatic CRC patients were encouraging. However the relatively small magnitude of improvement in PFS was an early sign of emerging resistance to cetuximab therapy. Therefore, further clinical and translational studies were conducted to elucidate possible underlying mechanisms related to EGFR blockade resistance.

EGFR mutations were considered as a possible mechanism for EGFR blockade resistance in CRC patients. However, in a clinical study, only one out of the 293 CRC patients was found to be harboring an EGFR mutation[[61](#_ENREF_61)]. Considering the rarity of EGFR mutations, they are unlikely to be a common cause of resistance to EGFR blockade in CRC patients.

As mentioned above, a retrospective study first revealed that the *KRAS-*mutant CRC patients did not benefit from cetuximab therapy[[52](#_ENREF_52)]. In a study by De Roock *et al*[[62](#_ENREF_62)], KRAS 13D mutation was reported to be associated with cetuximab response unlike other *KRAS* mutations. However another retrospective study did not confirm this favorable outcome[[63](#_ENREF_63)]. Whether *KRAS* 13D-mutant CRC tumors have a distinct clinical behavior from other *KRAS* mutations warrants further study. Similar to KRAS, a clinical study found NRAS to be a biomarker of anti-EGFR antibody resistance in CRC patients[[64](#_ENREF_64)]. This association of NRAS mutations with EGFR blockade resistance needs to be validated in future studies.

Since disruptions downstream of EGFR cause autonomous activation of the signaling pathway and potential intrinsic resistance to EGFR blockade, clinical studies also investigated the utility of *BRAF* mutations as a biomarker in CRC patients (Figure 2). In two clinical trials, patients with CRC harboring *BRAF* mutations were reported to have a poor response to cetuximab; indicating *BRAF* mutations could also limit the efficacy of anti-EGFR treatment[[58](#_ENREF_58),[65](#_ENREF_65)]. A large retrospective multicenter study looking at survival in patients with metastatic CRC and their mutation status; also reported similar findings[[64](#_ENREF_64)]. Although current evidence strongly suggests that *BRAF* mutations might be a negative biomarker for monoclonal anti-EGFR treatment, guidelines do not currently preclude such patients from this targeted treatment approach.

A study of 23 *PIK3CA*-mutant metastatic CRC patients reported no resistance to anti-EGFR treatment[[66](#_ENREF_66)]. However, in another cohort of 15 *PIK3CA*-mutant CRC patients, no objective response to panitumumab and cetuximab treatment was observed[[67](#_ENREF_67)]. A recent study of patients with metastatic CRC harboring wild-type KRAS showed a trend towards improved PFS in patients with wild-type PIK3CA compared to *PI3KCA*-mutant patients who received cetuximab either as a monotherapy or in combination with chemotherapy (*P* = 0.06)[[68](#_ENREF_68)]. Furthermore, a meta-analysis of 576 CRC patients reported a significantly lower PFS in patients harboring a *PIK3CA* mutation compared to patients with wild-type PIK3CA when treated with EGFR blockade[[69](#_ENREF_69)]. Although a majority of the aforementioned studies suggest resistance to EGFR blockade in *PIK3CA*-mutant metastatic CRC patients with wild-type KRAS, the absence of a consensus precludes making a clear conclusion in this specific patient group. A recent study investigated the role of PTEN expression in anti-EGFR blockade therapy and reported potential resistance to cetuximab treatment in metastatic CRC patients with low PTEN expression[[70](#_ENREF_70)]. Another study also demonstrated a significantly diminished response and worse PFS in patients with loss of PTEN function (32 wk *vs* 14 wk, *P* < 0.0001)[[71](#_ENREF_71)]. Loss of PTEN expression was also studied in patients with KRAS wild-type CRC which again suggested a lack of benefit from EGFR blockade[[68](#_ENREF_68)]. While accumulating evidence supports the hypothesis that PTEN loss may result in potential intrinsic resistance to EGFR blockade in CRC patients, further studies are needed to understand exact role of dysregulation of this gene.

The *MET* proto-oncogene, a receptor tyrosine kinase that belongs to the hepatocyte growth factor receptor, is also related to EGFR blockade resistance in CRC patients[[72](#_ENREF_72)]. A mechanistic study suggested that, resistance essentially arises in cancer stem cells *via* increased rebound activity of the *MET* oncogene upon inhibition of EGFR signaling by monoclonal antibodies[[73](#_ENREF_73)]. Another study identified increased Met activity driven by oncogenic Src and this upregulation was found to be related to cetuximab resistance[[74](#_ENREF_74)]. Increased TGF-α expression mediated by the Met oncogene could be also another oncogenic pathway related to cetuximab resistance[[75](#_ENREF_75)]. A mechanistic study reported that inhibition of both the Met and EGFR pathways by a bispecific monoclonal antibody may abrogate EGFR blockade resistance[[76](#_ENREF_76)]. Although these studies suggest that upregulation of this tyrosine kinase pathway may be related to EGFR blockade resistance, the exact mechanism of resistance with Met activity is yet to be elucidated.

**POSSIBLE MECHANISMS OF RESISTANCE IN WILD TYPE KRAS PATIENTS**

The response to EGFR blockade even in metastatic CRC patients with wild-type KRAS is unfortunately limited: following an initial honeymoon period, a majority of patients develop disease progression within months of initiation[[77](#_ENREF_77)]. Researchers investigated pathways possibly related to resistance in wild-type KRAS patients. An animal model study demonstrated that human epidermal growth factor receptor 2 (HER-2) amplification was associated with cetuximab resistance in a subset of metastatic CRC patients with wild-type KRAS, NRAS, BRAF and PIK3CA[[78](#_ENREF_78)]. The authors also reported prolonged responses with concurrent inhibition of HER-2 and EGFR in their model. Another mechanistic cell line study corroborated the association of aberrant ERBB2 (HER 2) signaling with EGFR blockade resistance[[79](#_ENREF_79)]. In a retrospective cohort study, HER-3 overexpression was also suggested to be a predictor of EGFR blockade resistance in metastatic CRC patients who underwent cetuximab and irinotecan treatment[[80](#_ENREF_80)]. Similar to the aforementioned studies, all patients included in this study were also harboring wild-type KRAS. A recent translational study examined the emergence of resistance in CRC cells sensitive to EGFR blockade[[81](#_ENREF_81)]. The authors examined the ultimate effect of continuous cetuximab treatment on the development of cetuximab-resistant clones. One of the cell lines developed a rescue mechanism by *KRAS* amplification and the other acquired a *KRAS* mutation. In the same study, the authors studied human samples and reported acquisition of *KRAS* mutation in 6 of 10 cases and *KRAS* amplification in another patient who developed resistance to cetuximab after an initial response. In another recent translational study, authors tested their theory with mathematical modeling; they hypothesized that *KRAS*-mutant CRC subclones might exist prior to initiation of anti-EGFR treatment[[82](#_ENREF_82)]. According to this model, anti-EGFR monoclonal therapy results in the selective proliferation of resistant subclones. The time required for these subclones to become radiologically detectable corresponds to the time of disease progression and development of EGFR blockade resistance. This hypothesis is also supported by tumor heterogeneity, a consequence of variant clones arising from a single parental clone due to continuous diverse genetic alterations throughout carcinogenesis and metastasis. These diverse genetic signatures have also been demonstrated to cause mixed clinical responses to cytotoxic chemotherapy. Moreover, a recent whole-exome sequencing study of 129 wild-type KRAS CRC tumor samples identified potential resistance mechanisms resulting from mutations in other growth factor pathways such as FGFR, and PDGFRA[[83](#_ENREF_83)]. This data suggests activation of potential bypass pathways related to other receptor tyrosine kinases abrogating the inhibitory effect of EGFR blockade.

Another possible resistance mechanism to anti-EGFR treatment could be attributed to ineffective structural interaction between the drug and its receptor[[84](#_ENREF_84)]. Mutations in the extracellular domain of EGFR hindering the binding of cetuximab to EGFR were demonstrated in 2 of 10 study participants with resistance to cetuximab. Moreover, one of those two cases responded to panitumumab. Since the number of the patients in the study was limited, this specific mutation should be further studied in larger populations.

Some recent studies indicate that certain signaling mediators which inhibit apoptosis could potentially rescue malignant cells during initiation of anti-EGFR monoclonal treatments[[85](#_ENREF_85),[86](#_ENREF_86)]. A recent study investigated acquired EGFR blockade resistance by analyzing circulating cancer cells and reported progressive genomic alterations throughout the acquisition of resistance suggesting that genomic instability in cancer cells may execute an important role in EGFR blockade resistance[[87](#_ENREF_87)]. Activation of other oncogenic tyrosine kinases by the local microenvironment with closed loop feedback might be another key mechanism of resistance in wild type KRAS patients[[73](#_ENREF_73)]. Further studies are required to elucidate the impact of tumor stroma on EGFR blockade resistance.

**FUTURE PERSPECTIVES**

Given the limited duration of responses to EGFR blockade and the inevitable development of resistance in both *KRAS* mutant and KRAS wild-type patients, studies were enrolled to optimize treatment outcomes. Based on potential mechanisms of resistance to EGFR blockade identified in preclinical studies, clinical trials have been designed to combat resistance. Considering the role of *PIK3CA* mutations, a phase II trial investigated the combination of cetuximab with PX-866, an irreversiblepan-isoform inhibitor of PI3KCA, in 86 patients with KRAS wild type metastatic CRC. The authors reported no improvement in PFS, objective response rate, or OS with the addition PX-866[[88](#_ENREF_88)]. Combinations of cetuximab with HER2 and HER3 targeting agents are currently being studied in clinical trials. The combination of cetuximab with pertuzumab (a monoclonal antibody that disrupts the dimerization of HER2) showed clinical activity, but produced intolerable side effects and toxicity[[89](#_ENREF_89)]. Studies combining cetuximab with HER 3 antagonists have demonstrated promising preliminary data, although final results are yet to be reported[[90](#_ENREF_90)].

A xenograft study investigated a new agent to overcome *EGFR* mutation-related resistance. Sym004, a novel mixture of two nonoverlapping anti-EGFR monoclonal antibodies, has demonstrated binding and ligand-dependent activation in patients with *EGFR* mutations conferring resistance to conventional anti-EGFR antibodies in functional studies[[91](#_ENREF_91)]. Phase I trials of Sym004 in metastatic CRC patients with wild type *KRAS* mutation and previous EGFR blockade response showed tumor radiologic regression in 17 of 39 patients (44%) and partial response in 5 patients (13%)[[92](#_ENREF_92)]. Phase II clinical trials of Sym004 and early phase studies of other targeting agents of the EGFR pathways are currently being investigated which may enlighten the utility of concurrent/simultaneous inhibition of prosurvival pathways to abrogate EGFR blockade resistance

**CONCLUSION**

Current state-of-the-science endorses clinical activity of the EGFR blockade in selected subsets of patients with treatment naïve and refractory metastatic CRC. However, growing evidence has advanced our understanding of the limitations of anti-EGFR treatment.

Although cetuximab and other monoclonal anti-EGFR antibodies effectively inhibit EGFR signaling; their clinical activity is limited to a short period of time. Disease heterogeneity, created by continuous and dynamic genetic alterations, distinct mutational signatures in the EGFR downstream signaling pathways, and rebound activation of other growth signals appears to be the primary driving force rescuing cancer cells from apoptosis. New subclones with new oncogenic fingerprints arising as a consequence of genomic instability, appear to be one of the most challenging factors in the era of targeted treatment. Frequently, this dynamic process and the associated genetic plasticity overcome the inhibitory effect of targeted agents and ultimately, disease progression occurs despite optimal treatment. Moreover, the addiction of cancer cells to a single oncogenic pathway appears to be limited, and the co-activation of rebound survival pathways further limits the impact of a single targeted agent. The lack of durability of the clinical responses to EGFR blockade observed in the aforementioned studies also represents the phenotypic characteristics of dynamic changes in genotype. Whether combinations of targeted agents along with alternate treatment cycles can overcome this acquired resistance requires further clinical studies. Studies are warranted to better understand the underpinnings of dynamic genomic alterations and its role in acquired resistance to targeting agents including EGFR blockades.

**REFERENCES**

1 **Jemal A**, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. *CA Cancer J Clin* 2011; **61**: 69-90 [PMID: 21296855 DOI: 10.3322/caac.20107]

2 **Siegel R**, Naishadham D, Jemal A. Cancer statistics, 2012. *CA Cancer J Clin* 2012; **62**: 10-29 [PMID: 22237781 DOI: 10.3322/caac.20138]

3 **Cohen S**, Carpenter G, King L. Epidermal growth factor-receptor-protein kinase interactions. Co-purification of receptor and epidermal growth factor-enhanced phosphorylation activity. *J Biol Chem* 1980; **255**: 4834-4842 [PMID: 6246084]

4 **Adamson ED**, Rees AR. Epidermal growth factor receptors. *Mol Cell Biochem* 1981; **34**: 129-152 [DOI: 10.1007/bf02359619]

5 **Roskoski R**. The ErbB/HER receptor protein-tyrosine kinases and cancer. *Biochem Biophys Res Commun* 2004; **319**: 1-11 [PMID: 15158434 DOI: 10.1016/j.bbrc.2004.04.150]

6 **Malumbres M**, Barbacid M. RAS oncogenes: the first 30 years. *Nat Rev Cancer* 2003; **3**: 459-465 [PMID: 12778136 DOI: 10.1038/nrc1097]

7 **Bos JL**. ras oncogenes in human cancer: a review. *Cancer Res* 1989; **49**: 4682-4689 [PMID: 2547513]

8 **Magudia K**, Lahoz A, Hall A. K-Ras and B-Raf oncogenes inhibit colon epithelial polarity establishment through up-regulation of c-myc. *J Cell Biol* 2012; **198**: 185-194 [PMID: 22826122 DOI: 10.1083/jcb.201202108]

9 **Torii S**, Yamamoto T, Tsuchiya Y, Nishida E. ERK MAP kinase in G cell cycle progression and cancer. *Cancer Sci* 2006; **97**: 697-702 [PMID: 16800820 DOI: 10.1111/j.1349-7006.2006.00244.x]

10 **Minden A**, Lin A, McMahon M, Lange-Carter C, Dérijard B, Davis RJ, Johnson GL, Karin M. Differential activation of ERK and JNK mitogen-activated protein kinases by Raf-1 and MEKK. *Science* 1994; **266**: 1719-1723 [PMID: 7992057]

11 **Haigis KM**, Kendall KR, Wang Y, Cheung A, Haigis MC, Glickman JN, Niwa-Kawakita M, Sweet-Cordero A, Sebolt-Leopold J, Shannon KM, Settleman J, Giovannini M, Jacks T. Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. *Nat Genet* 2008; **40**: 600-608 [PMID: 18372904 DOI: 10.1038/ng.115]

12 **Tuveson DA**, Shaw AT, Willis NA, Silver DP, Jackson EL, Chang S, Mercer KL, Grochow R, Hock H, Crowley D, Hingorani SR, Zaks T, King C, Jacobetz MA, Wang L, Bronson RT, Orkin SH, DePinho RA, Jacks T. Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. *Cancer Cell* 2004; **5**: 375-387 [PMID: 15093544]

13 **Parker PJ**, Waterfield MD. Phosphatidylinositol 3-kinase: a novel effector. *Cell Growth Differ* 1992; **3**: 747-752 [PMID: 1332743]

14 **Kennedy AL**, Morton JP, Manoharan I, Nelson DM, Jamieson NB, Pawlikowski JS, McBryan T, Doyle B, McKay C, Oien KA, Enders GH, Zhang R, Sansom OJ, Adams PD. Activation of the PIK3CA/AKT pathway suppresses senescence induced by an activated RAS oncogene to promote tumorigenesis. *Mol Cell* 2011; **42**: 36-49 [PMID: 21474066 DOI: 10.1016/j.molcel.2011.02.020]

15 **Asnaghi L**, Bruno P, Priulla M, Nicolin A. mTOR: a protein kinase switching between life and death. *Pharmacol Res* 2004; **50**: 545-549 [PMID: 15501691 DOI: 10.1016/j.phrs.2004.03.007]

16 **Chan AT**, Ogino S, Fuchs CS. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. *N Engl J Med* 2007; **356**: 2131-2142 [PMID: 17522398 DOI: 10.1056/NEJMoa067208]

17 **Samuels Y**, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JK, Markowitz S, Kinzler KW, Vogelstein B, Velculescu VE. High frequency of mutations of the PIK3CA gene in human cancers. *Science* 2004; **304**: 554 [PMID: 15016963 DOI: 10.1126/science.1096502]

18 **Samuels Y**, Diaz LA, Schmidt-Kittler O, Cummins JM, Delong L, Cheong I, Rago C, Huso DL, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. *Cancer Cell* 2005; **7**: 561-573 [PMID: 15950905 DOI: 10.1016/j.ccr.2005.05.014]

19 **Roskoski R**. RAF protein-serine/threonine kinases: structure and regulation. *Biochem Biophys Res Commun* 2010; **399**: 313-317 [PMID: 20674547 DOI: 10.1016/j.bbrc.2010.07.092]

20 **Davies H**, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA. Mutations of the BRAF gene in human cancer. *Nature* 2002; **417**: 949-954 [PMID: 12068308 DOI: 10.1038/nature00766]

21 **McCubrey JA**, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala F, Libra M, Basecke J, Evangelisti C, Martelli AM, Franklin RA. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. *Biochim Biophys Acta* 2007; **1773**: 1263-1284 [PMID: 17126425 DOI: 10.1016/j.bbamcr.2006.10.001]

22 **Ikehara N**, Semba S, Sakashita M, Aoyama N, Kasuga M, Yokozaki H. BRAF mutation associated with dysregulation of apoptosis in human colorectal neoplasms. *Int J Cancer* 2005; **115**: 943-950 [PMID: 15729718 DOI: 10.1002/ijc.20957]

23 **Ikenoue T**, Hikiba Y, Kanai F, Tanaka Y, Imamura J, Imamura T, Ohta M, Ijichi H, Tateishi K, Kawakami T, Aragaki J, Matsumura M, Kawabe T, Omata M. Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors. *Cancer Res* 2003; **63**: 8132-8137 [PMID: 14678966]

24 **Sakamoto K**, Maeda S, Hikiba Y, Nakagawa H, Hayakawa Y, Shibata W, Yanai A, Ogura K, Omata M. Constitutive NF-kappaB activation in colorectal carcinoma plays a key role in angiogenesis, promoting tumor growth. *Clin Cancer Res* 2009; **15**: 2248-2258 [PMID: 19276252 DOI: 10.1158/1078-0432.CCR-08-1383]

25 **Jorissen RN**, Walker F, Pouliot N, Garrett TP, Ward CW, Burgess AW. Epidermal growth factor receptor: mechanisms of activation and signalling. *Exp Cell Res* 2003; **284**: 31-53 [PMID: 12648464]

26 **Osherov N**, Levitzki A. Epidermal-growth-factor-dependent activation of the src-family kinases. *Eur J Biochem* 1994; **225**: 1047-1053 [PMID: 7525285]

27 **Mao W**, Irby R, Coppola D, Fu L, Wloch M, Turner J, Yu H, Garcia R, Jove R, Yeatman TJ. Activation of c-Src by receptor tyrosine kinases in human colon cancer cells with high metastatic potential. *Oncogene* 1997; **15**: 3083-3090 [PMID: 9444956 DOI: 10.1038/sj.onc.1201496]

28 **Biscardi JS**, Tice DA, Parsons SJ. c-Src, receptor tyrosine kinases, and human cancer. *Adv Cancer Res* 1999; **76**: 61-119 [PMID: 10218099]

29 **Aligayer H**, Boyd DD, Heiss MM, Abdalla EK, Curley SA, Gallick GE. Activation of Src kinase in primary colorectal carcinoma: an indicator of poor clinical prognosis. *Cancer* 2002; **94**: 344-351 [PMID: 11900220 DOI: 10.1002/cncr.10221]

30 **Irby RB**, Mao W, Coppola D, Kang J, Loubeau JM, Trudeau W, Karl R, Fujita DJ, Jove R, Yeatman TJ. Activating SRC mutation in a subset of advanced human colon cancers. *Nat Genet* 1999; **21**: 187-190 [PMID: 9988270 DOI: 10.1038/5971]

31 **Kotenko SV**, Pestka S. Jak-Stat signal transduction pathway through the eyes of cytokine class II receptor complexes. *Oncogene* 2000; **19**: 2557-2565 [PMID: 10851054 DOI: 10.1038/sj.onc.1203524]

32 **David M**, Wong L, Flavell R, Thompson SA, Wells A, Larner AC, Johnson GR. STAT activation by epidermal growth factor (EGF) and amphiregulin. Requirement for the EGF receptor kinase but not for tyrosine phosphorylation sites or JAK1. *J Biol Chem* 1996; **271**: 9185-9188 [PMID: 8621573]

33 **Bromberg J**. Stat proteins and oncogenesis. *J Clin Invest* 2002; **109**: 1139-1142 [PMID: 11994401 DOI: 10.1172/JCI15617]

34 **Corvinus FM**, Orth C, Moriggl R, Tsareva SA, Wagner S, Pfitzner EB, Baus D, Kaufmann R, Huber LA, Zatloukal K, Beug H, Ohlschläger P, Schütz A, Halbhuber KJ, Friedrich K. Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth. *Neoplasia* 2005; **7**: 545-555 [PMID: 16036105]

35 **Lockhart AC**, Berlin JD. The epidermal growth factor receptor as a target for colorectal cancer therapy. *Semin Oncol* 2005; **32**: 52-60 [PMID: 15726506 DOI: 10.1053/j.seminoncol.2004.09.036]

36 **Mendelsohn J**, Baselga J. Epidermal growth factor receptor targeting in cancer. *Semin Oncol* 2006; **33**: 369-385 [PMID: 16890793 DOI: 10.1053/j.seminoncol.2006.04.003]

37 **Sato JD**, Kawamoto T, Le AD, Mendelsohn J, Polikoff J, Sato GH. Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. *Mol Biol Med* 1983; **1**: 511-529 [PMID: 6094961]

38 **Masui H**, Kawamoto T, Sato JD, Wolf B, Sato G, Mendelsohn J. Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. *Cancer Res* 1984; **44**: 1002-1007 [PMID: 6318979]

39 **Goldstein NI**, Prewett M, Zuklys K, Rockwell P, Mendelsohn J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. *Clin Cancer Res* 1995; **1**: 1311-1318 [PMID: 9815926]

40 **Mendelsohn J**, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. *J Clin Oncol* 2003; **21**: 2787-2799 [PMID: 12860957 DOI: 10.1200/JCO.2003.01.504]

41 **Fracasso PM**, Burris H, Arquette MA, Govindan R, Gao F, Wright LP, Goodner SA, Greco FA, Jones SF, Willcut N, Chodkiewicz C, Pathak A, Springett GM, Simon GR, Sullivan DM, Marcelpoil R, Mayfield SD, Mauro D, Garrett CR. A phase 1 escalating single-dose and weekly fixed-dose study of cetuximab: pharmacokinetic and pharmacodynamic rationale for dosing. *Clin Cancer Res* 2007; **13**: 986-993 [PMID: 17289894 DOI: 10.1158/1078-0432.CCR-06-1542]

42 **Kawamoto T**, Sato JD, Le A, Polikoff J, Sato GH, Mendelsohn J. Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody. *Proc Natl Acad Sci USA* 1983; **80**: 1337-1341 [PMID: 6298788]

43 **Mendelsohn J**, Baselga J. The EGF receptor family as targets for cancer therapy. *Oncogene* 2000; **19**: 6550-6565 [PMID: 11426640 DOI: 10.1038/sj.onc.1204082]

44 **Prewett MC**, Hooper AT, Bassi R, Ellis LM, Waksal HW, Hicklin DJ. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. *Clin Cancer Res* 2002; **8**: 994-1003 [PMID: 12006511]

45 **Baselga J**, Pfister D, Cooper MR, Cohen R, Burtness B, Bos M, D'Andrea G, Seidman A, Norton L, Gunnett K, Falcey J, Anderson V, Waksal H, Mendelsohn J. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. *J Clin Oncol* 2000; **18**: 904-914 [PMID: 10673534]

46 **Saltz L**, Rubin M, Hochster H, Tchekmeydian N, Waksal H, Needle M, LoBuglio A. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). *Proc Am Soc Clin Oncol* 2001

47 **Saltz LB**, Meropol NJ, Loehrer PJ, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. *J Clin Oncol* 2004; **22**: 1201-1208 [PMID: 14993230 DOI: 10.1200/JCO.2004.10.182]

48 **Cunningham D**, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. *N Engl J Med* 2004; **351**: 337-345 [PMID: 15269313 DOI: 10.1056/NEJMoa033025]

49 **Jonker DJ**, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, Berry SR, Krahn M, Price T, Simes RJ, Tebbutt NC, van Hazel G, Wierzbicki R, Langer C, Moore MJ. Cetuximab for the treatment of colorectal cancer. *N Engl J Med* 2007; **357**: 2040-2048 [PMID: 18003960 DOI: 10.1056/NEJMoa071834]

50 **Pippas A**, Lenz H, Mayer R, Mirtsching B, Cohn A, Windt P, Van Cutsem E. Analysis of EGFR status in metastatic colorectal cancer patients treated with cetuximab monotherapy*. J Clin Oncol* (Meeting Abstracts), 2005

51 **Van Cutsem E**, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. *N Engl J Med* 2009; **360**: 1408-1417 [PMID: 19339720 DOI: 10.1056/NEJMoa0805019]

52 **Van Cutsem E**, Köhne CH, Láng I, Folprecht G, Nowacki MP, Cascinu S, Shchepotin I, Maurel J, Cunningham D, Tejpar S, Schlichting M, Zubel A, Celik I, Rougier P, Ciardiello F. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. *J Clin Oncol* 2011; **29**: 2011-2019 [PMID: 21502544 DOI: 10.1200/JCO.2010.33.5091]

53 **Bokemeyer C**, Bondarenko I, Hartmann JT, de Braud F, Schuch G, Zubel A, Celik I, Schlichting M, Koralewski P. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. *Ann Oncol* 2011; **22**: 1535-1546 [PMID: 21228335 DOI: 10.1093/annonc/mdq632]

54 **Alberts SR**, Sargent DJ, Nair S, Mahoney MR, Mooney M, Thibodeau SN, Smyrk TC, Sinicrope FA, Chan E, Gill S, Kahlenberg MS, Shields AF, Quesenberry JT, Webb TA, Farr GH, Pockaj BA, Grothey A, Goldberg RM. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. *JAMA* 2012; **307**: 1383-1393 [PMID: 22474202 DOI: 10.1001/jama.2012.385]

55 **Folprecht G**, Gruenberger T, Bechstein WO, Raab HR, Lordick F, Hartmann JT, Lang H, Frilling A, Stoehlmacher J, Weitz J, Konopke R, Stroszczynski C, Liersch T, Ockert D, Herrmann T, Goekkurt E, Parisi F, Köhne CH. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. *Lancet Oncol* 2010; **11**: 38-47 [PMID: 19942479 DOI: 10.1016/S1470-2045(09)70330-4]

56 **Van Cutsem E**, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, Canon JL, Van Laethem JL, Maurel J, Richardson G, Wolf M, Amado RG. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. *J Clin Oncol* 2007; **25**: 1658-1664 [PMID: 17470858 DOI: 10.1200/JCO.2006.08.1620]

57 **Amado RG**, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. *J Clin Oncol* 2008; **26**: 1626-1634 [PMID: 18316791 DOI: 10.1200/JCO.2007.14.7116]

58 **Di Nicolantonio F**, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. *J Clin Oncol* 2008; **26**: 5705-5712 [PMID: 19001320 DOI: 10.1200/JCO.2008.18.0786]

59 **Douillard JY**, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocákova I, Ruff P, Błasińska-Morawiec M, Šmakal M, Canon JL, Rother M, Oliner KS, Wolf M, Gansert J. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. *J Clin Oncol* 2010; **28**: 4697-4705 [PMID: 20921465 DOI: 10.1200/JCO.2009.27.4860]

60 **Sastre J**, Massuti B, Pulido G, Guillén-Ponce C, Benavides M, Manzano JL, Reboredo M, Rivera F, Grávalos C, Safont MJ, Martínez Villacampa M, Llovet P, Dotor E, Díaz-Rubio E, Aranda E. First-line single-agent panitumumab in frail elderly patients with wild-type KRAS metastatic colorectal cancer and poor prognostic factors: A phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours. *Eur J Cancer* 2015; **51**: 1371-1380 [PMID: 25963019 DOI: 10.1016/j.ejca.2015.04.013]

61 **Barber TD**, Vogelstein B, Kinzler KW, Velculescu VE. Somatic mutations of EGFR in colorectal cancers and glioblastomas. *N Engl J Med* 2004; **351**: 2883 [PMID: 15625347 DOI: 10.1056/NEJM200412303512724]

62 **De Roock W**, Jonker DJ, Di Nicolantonio F, Sartore-Bianchi A, Tu D, Siena S, Lamba S, Arena S, Frattini M, Piessevaux H, Van Cutsem E, O'Callaghan CJ, Khambata-Ford S, Zalcberg JR, Simes J, Karapetis CS, Bardelli A, Tejpar S. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. *JAMA* 2010; **304**: 1812-1820 [PMID: 20978259 DOI: 10.1001/jama.2010.1535]

63 **Peeters M**, Douillard JY, Van Cutsem E, Siena S, Zhang K, Williams R, Wiezorek J. Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab. *J Clin Oncol* 2013; **31**: 759-765 [PMID: 23182985 DOI: 10.1200/JCO.2012.45.1492]

64 **De Roock W**, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, Kalogeras KT, Kotoula V, Papamichael D, Laurent-Puig P, Penault-Llorca F, Rougier P, Vincenzi B, Santini D, Tonini G, Cappuzzo F, Frattini M, Molinari F, Saletti P, De Dosso S, Martini M, Bardelli A, Siena S, Sartore-Bianchi A, Tabernero J, Macarulla T, Di Fiore F, Gangloff AO, Ciardiello F, Pfeiffer P, Qvortrup C, Hansen TP, Van Cutsem E, Piessevaux H, Lambrechts D, Delorenzi M, Tejpar S. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. *Lancet Oncol* 2010; **11**: 753-762 [PMID: 20619739 DOI: 10.1016/S1470-2045(10)70130-3]

65 **Laurent-Puig P**, Cayre A, Manceau G, Buc E, Bachet JB, Lecomte T, Rougier P, Lievre A, Landi B, Boige V, Ducreux M, Ychou M, Bibeau F, Bouché O, Reid J, Stone S, Penault-Llorca F. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. *J Clin Oncol* 2009; **27**: 5924-5930 [PMID: 19884556 DOI: 10.1200/JCO.2008.21.6796]

66 **Prenen H**, De Schutter J, Jacobs B, De Roock W, Biesmans B, Claes B, Lambrechts D, Van Cutsem E, Tejpar S. PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. *Clin Cancer Res* 2009; **15**: 3184-3188 [PMID: 19366826 DOI: 10.1158/1078-0432.CCR-08-2961]

67 **Sartore-Bianchi A**, Martini M, Molinari F, Veronese S, Nichelatti M, Artale S, Di Nicolantonio F, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. *Cancer Res* 2009; **69**: 1851-1857 [PMID: 19223544 DOI: 10.1158/0008-5472.CAN-08-2466]

68 **Sood A**, McClain D, Maitra R, Basu-Mallick A, Seetharam R, Kaubisch A, Rajdev L, Mariadason JM, Tanaka K, Goel S. PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer. *Clin Colorectal Cancer* 2012; **11**: 143-150 [PMID: 22285706 DOI: 10.1016/j.clcc.2011.12.001]

69 **Mao C**, Yang ZY, Hu XF, Chen Q, Tang JL. PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis. *Ann Oncol* 2012; **23**: 1518-1525 [PMID: 22039088 DOI: 10.1093/annonc/mdr464]

70 **Loupakis F**, Pollina L, Stasi I, Ruzzo A, Scartozzi M, Santini D, Masi G, Graziano F, Cremolini C, Rulli E, Canestrari E, Funel N, Schiavon G, Petrini I, Magnani M, Tonini G, Campani D, Floriani I, Cascinu S, Falcone A. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. *J Clin Oncol* 2009; **27**: 2622-2629 [PMID: 19398573 DOI: 10.1200/JCO.2008.20.2796]

71 **Li FH**, Shen L, Li ZH, Luo HY, Qiu MZ, Zhang HZ, Li YH, Xu RH. Impact of KRAS mutation and PTEN expression on cetuximab-treated colorectal cancer. *World J Gastroenterol* 2010; **16**: 5881-5888 [PMID: 21155011]

72 **Krumbach R**, Schüler J, Hofmann M, Giesemann T, Fiebig HH, Beckers T. Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: activation of MET as one mechanism for drug resistance. *Eur J Cancer* 2011; **47**: 1231-1243 [PMID: 21273060 DOI: 10.1016/j.ejca.2010.12.019]

73 **Luraghi P**, Reato G, Cipriano E, Sassi F, Orzan F, Bigatto V, De Bacco F, Menietti E, Han M, Rideout WM, Perera T, Bertotti A, Trusolino L, Comoglio PM, Boccaccio C. MET signaling in colon cancer stem-like cells blunts the therapeutic response to EGFR inhibitors. *Cancer Res* 2014; **74**: 1857-1869 [PMID: 24448239 DOI: 10.1158/0008-5472.CAN-13-2340-T]

74 **Song N**, Liu S, Zhang J, Liu J, Xu L, Liu Y, Qu X. Cetuximab-induced MET activation acts as a novel resistance mechanism in colon cancer cells. *Int J Mol Sci* 2014; **15**: 5838-5851 [PMID: 24714091 DOI: 10.3390/ijms15045838]

75 **Troiani T**, Martinelli E, Napolitano S, Vitagliano D, Ciuffreda LP, Costantino S, Morgillo F, Capasso A, Sforza V, Nappi A, De Palma R, D'Aiuto E, Berrino L, Bianco R, Ciardiello F. Increased TGF-α as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells. *Clin Cancer Res* 2013; **19**: 6751-6765 [PMID: 24122793 DOI: 10.1158/1078-0432.CCR-13-0423]

76 **Castoldi R**, Ecker V, Wiehle L, Majety M, Busl-Schuller R, Asmussen M, Nopora A, Jucknischke U, Osl F, Kobold S, Scheuer W, Venturi M, Klein C, Niederfellner G, Sustmann C. A novel bispecific EGFR/Met antibody blocks tumor-promoting phenotypic effects induced by resistance to EGFR inhibition and has potent antitumor activity. *Oncogene* 2013; **32**: 5593-5601 [PMID: 23812422 DOI: 10.1038/onc.2013.245]

77 **Karapetis CS**, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. *N Engl J Med* 2008; **359**: 1757-1765 [PMID: 18946061 DOI: 10.1056/NEJMoa0804385]

78 **Bertotti A**, Migliardi G, Galimi F, Sassi F, Torti D, Isella C, Corà D, Di Nicolantonio F, Buscarino M, Petti C, Ribero D, Russolillo N, Muratore A, Massucco P, Pisacane A, Molinaro L, Valtorta E, Sartore-Bianchi A, Risio M, Capussotti L, Gambacorta M, Siena S, Medico E, Sapino A, Marsoni S, Comoglio PM, Bardelli A, Trusolino L. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. *Cancer Discov* 2011; **1**: 508-523 [PMID: 22586653 DOI: 10.1158/2159-8290.CD-11-0109]

79 **Yonesaka K**, Zejnullahu K, Okamoto I, Satoh T, Cappuzzo F, Souglakos J, Ercan D, Rogers A, Roncalli M, Takeda M, Fujisaka Y, Philips J, Shimizu T, Maenishi O, Cho Y, Sun J, Destro A, Taira K, Takeda K, Okabe T, Swanson J, Itoh H, Takada M, Lifshits E, Okuno K, Engelman JA, Shivdasani RA, Nishio K, Fukuoka M, Varella-Garcia M, Nakagawa K, Jänne PA. Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. *Sci Transl Med* 2011; **3**: 99ra86 [PMID: 21900593 DOI: 10.1126/scitranslmed.3002442]

80 **Scartozzi M**, Mandolesi A, Giampieri R, Bittoni A, Pierantoni C, Zaniboni A, Galizia E, Giustini L, Silva RR, Bisonni R, Berardi R, Biscotti T, Biagetti S, Bearzi I, Cascinu S. The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan and cetuximab. *Oncologist* 2011; **16**: 53-60 [PMID: 21212430 DOI: 10.1634/theoncologist.2010-0119]

81 **Misale S**, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, Valtorta E, Schiavo R, Buscarino M, Siravegna G, Bencardino K, Cercek A, Chen CT, Veronese S, Zanon C, Sartore-Bianchi A, Gambacorta M, Gallicchio M, Vakiani E, Boscaro V, Medico E, Weiser M, Siena S, Di Nicolantonio F, Solit D, Bardelli A. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. *Nature* 2012; **486**: 532-536 [PMID: 22722830 DOI: 10.1038/nature11156]

82 **Diaz LA**, Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, Allen B, Bozic I, Reiter JG, Nowak MA, Kinzler KW, Oliner KS, Vogelstein B. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. *Nature* 2012; **486**: 537-540 [PMID: 22722843 DOI: 10.1038/nature11219]

83 **Bertotti A**, Papp E, Jones S, Adleff V, Anagnostou V, Lupo B, Sausen M, Phallen J, Hruban CA, Tokheim C, Niknafs N, Nesselbush M, Lytle K, Sassi F, Cottino F, Migliardi G, Zanella ER, Ribero D, Russolillo N, Mellano A, Muratore A, Paraluppi G, Salizzoni M, Marsoni S, Kragh M, Lantto J, Cassingena A, Li QK, Karchin R, Scharpf R, Sartore-Bianchi A, Siena S, Diaz LA, Trusolino L, Velculescu VE. The genomic landscape of response to EGFR blockade in colorectal cancer. *Nature* 2015; **526**: 263-267 [PMID: 26416732 DOI: 10.1038/nature14969]

84 **Montagut C**, Dalmases A, Bellosillo B, Crespo M, Pairet S, Iglesias M, Salido M, Gallen M, Marsters S, Tsai SP, Minoche A, Seshagiri S, Serrano S, Himmelbauer H, Bellmunt J, Rovira A, Settleman J, Bosch F, Albanell J. Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer. *Nat Med* 2012; **18**: 221-223 [PMID: 22270724 DOI: 10.1038/nm.2609]

85 **Rosa R**, Marciano R, Malapelle U, Formisano L, Nappi L, D'Amato C, D'Amato V, Damiano V, Marfè G, Del Vecchio S, Zannetti A, Greco A, De Stefano A, Carlomagno C, Veneziani BM, Troncone G, De Placido S, Bianco R. Sphingosine kinase 1 overexpression contributes to cetuximab resistance in human colorectal cancer models. *Clin Cancer Res* 2013; **19**: 138-147 [PMID: 23166225 DOI: 10.1158/1078-0432.CCR-12-1050]

86 **Scartozzi M**, Giampieri R, Maccaroni E, Mandolesi A, Biagetti S, Alfonsi S, Giustini L, Loretelli C, Faloppi L, Bittoni A, Bianconi M, Del Prete M, Bearzi I, Cascinu S. Phosphorylated AKT and MAPK expression in primary tumours and in corresponding metastases and clinical outcome in colorectal cancer patients receiving irinotecan-cetuximab. *J Transl Med* 2012; **10**: 71 [PMID: 22490361 DOI: 10.1186/1479-5876-10-71]

87 **Siravegna G**, Mussolin B, Buscarino M, Corti G, Cassingena A, Crisafulli G, Ponzetti A, Cremolini C, Amatu A, Lauricella C, Lamba S, Hobor S, Avallone A, Valtorta E, Rospo G, Medico E, Motta V, Antoniotti C, Tatangelo F, Bellosillo B, Veronese S, Budillon A, Montagut C, Racca P, Marsoni S, Falcone A, Corcoran RB, Di Nicolantonio F, Loupakis F, Siena S, Sartore-Bianchi A, Bardelli A. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. *Nat Med* 2015; **21**: 795-801 [PMID: 26030179 DOI: 10.1038/nm.3870]

88 **Bowles DW**, Kochenderfer M, Cohn A, Sideris L, Nguyen N, Cline-Burkhardt V, Schnadig I, Choi M, Nabell L, Chaudhry A, Ruxer R, Ucar A, Hausman D, Walker L, Spira A, Jimeno A. A Randomized, Phase II Trial of Cetuximab With or Without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients With Metastatic Colorectal Carcinoma. *Clin Colorectal Cancer* 2016; **pii**: S1533-0028(16)30029-9 [PMID: 27118441 DOI: 10.1016/j.clcc.2016.03.004]

89 **Rubinson DA**, Hochster HS, Ryan DP, Wolpin BM, McCleary NJ, Abrams TA, Chan JA, Iqbal S, Lenz HJ, Lim D, Rose J, Bekaii-Saab T, Chen HX, Fuchs CS, Ng K. Multi-drug inhibition of the HER pathway in metastatic colorectal cancer: results of a phase I study of pertuzumab plus cetuximab in cetuximab-refractory patients. *Invest New Drugs* 2014; **32**: 113-122 [PMID: 23568716 DOI: 10.1007/s10637-013-9956-5]

90 **Temraz S**, Mukherji D, Shamseddine A. Dual targeting of HER3 and EGFR in colorectal tumors might overcome anti-EGFR resistance. *Crit Rev Oncol Hematol* 2016; **101**: 151-157 [PMID: 27017409 DOI: 10.1016/j.critrevonc.2016.03.009]

91 **Sánchez-Martín FJ**, Bellosillo B, Gelabert-Baldrich M, Dalmases A, Cañadas I, Vidal J, Martinez A, Argilés G, Siravegna G, Arena S, Koefoed K, Visa L, Arpí O, Horak ID, Iglesias M, Stroh C, Kragh M, Rovira A, Albanell J, Tabernero J, Bardelli A, Montagut C. The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer. *Clin Cancer Res* 2016; **22**: 3260-3267 [PMID: 26888827 DOI: 10.1158/1078-0432.CCR-15-2400]


92 **Dienstmann R**, Patnaik A, Garcia-Carbonero R, Cervantes A, Benavent M, Roselló S, Tops BB, van der Post RS, Argilés G, Skartved NJ, Hansen UH, Hald R, Pedersen MW, Kragh M, Horak ID, Braun S, Van Cutsem E, Tolcher AW, Tabernero J. Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer. *Cancer Discov* 2015; **5**: 598-609 [PMID: 25962717 DOI: 10.1158/2159-8290.CD-14-1432]

**P-Reviewer:** Milone M, Zoller M **S-Editor:** Ji FF **L-Editor: E-Editor:**


**Table 1 Clinical trials investigating the impact of epidermal growth factor receptor blockades in colorectal cancer patients**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Ref. | Year | Sample size | Mutation status | Treatment groups | Special considerations | Summarized findings |
| Saltz *et al*[49] |  | 120 | EGFR + | Cetuximab plus Irinotecan |  | 22.5% major objective response rate  17% radiologic response rate |
| Saltz *et al*[50] | 2004 | 57 | EGFR + | Cetuximab |  | 9% (CI: 3% to 19%) partial response  Median survival of 6.4 mo. *P* value ?? |
| Cunningham  *et al*[51] | 2004 | 329 | EGFR + | Cetuximab plus irinotecan *vs* cetuximab alone |  | 22.9% partial response in combination arm, 10.8% partial response in the cetuximab monotherapy arm  No difference in OS |
| Jonker *et al*[52] | 2007 | 572 | EGFR + | Cetuximab compared to best supportive care |  | 6.1 mo OS in treatment arm *vs* 4.6 mo with supportive care. *P* = 0.005  Quality of life was better preserved in the cetuximab group (*P* < 0.05) |
| Van Cutsem *et al*[59] | 2007 | 463 | EGFR+ | Panitumumab *vs* best supportive care |  | Median PFS 8 wk in treatment arm compared to 7.3 wk in patients receiving supportive care (HR 0.54; *P* < 0.0001) |
| Amado *et al*[60] | 2008 | 427 | EGFR+  Wild type KRAS *vs* mutant *KRAS* | Panitumumab *vs* best supportive care | Reanalysis of Van Cutsem 2007 | In patients with wild type KRAS median PFS was 12.3 wk for panitumumab *vs* 7.3 wk for supportive care  Response rates to panitumumab was 17% for patients with wild type KRAS compared to 0% in patients with mutant *KRAS* |
| VanCutsem *et al*[54] CRYSTAL Trial | 2009 | 1198 | EGFR + | Cetuximab plus FOLFIRI *vs* FOLFIRI alone |  | HR for PFS in combination therapy 0.85 (*P* = 0.048) when compared to FOLFIRI alone There was no difference in OS (HR 0.93; *P* = 0.31)  Although not significant PFS was improved with cetuximab in patients with wild-type-KRAS (HR 0.68; *P* = 0.07) |
| Folprecht *et al*[58]  CELIM trial | 2010 | 113 | Wild type KRAS *vs* mutant *KRAS* | Cetuximab plusFOLFOX *vs* Cetuximab plus FOLFIRI *vs* historical controls | Neoadjuvant setting | No survival difference between the two groups  Higher response rates compared to historical controls (FOLFOX and FOLFIRI)  Total 36 of 116 patients were able to receive R0 resection  Improved outcomes limited to patients with wild type KRAS |
| VanCutsem *et al*[55] | 2011 | 1198 | EGFR+ Wild type KRAS *vs* mutant KRAS | Cetuximab plus FOLFIRI *vs* FOLFIRI alone  Wild type KRAS *vs* mutant *KRAS* | Reanalysis of data from CRYSTAL trial | Patients with wild type KRAS had improvements in OS from 20 to 23.5 mo PFS from 8.4 to 9.9 mo and response rates 39.7% to 57.3% with addition of Cetuximab to FOLFIRI |
| Bokemeyer *et al*[56]  OPUS study | 2011 | 315 | Wild type KRAS/BRAF *vs* mutant *KRAS/BRAF* | Cetuximab plus FOLFOX |  | Improved PFS (HR 0.567) and response (OR 2.55) in patients with KRAS wild-type tumors |
| Alberts *et al*[57]  N0137 trial | 2012 | 2686 | Wild type KRAS *vs* mutant *KRAS* | Cetuximab plus FOLFOX *vs* FOLFOX alone | Locally advanced disease | No additional benefit of Cetuximab when added to FOLFOX-6 regimen in the setting of locally advance disease |

EGFR: Epidermal growth factor receptor; PFS: Progression free survival; OS: Overall survival.



**Figure 1 Epidermal growth factor receptor signaling along with co-activated other receptor tyrosine kinases.** EGFR: Epidermal growth factor receptor; PIK3CA: Phosphatidylinositol 3-kinase; mTOR: Mechanistic target of rapamycin.

****

**Figure 2 Possible resistance pathways to epidermal growth factor receptor blockade; gain of mutations in KRAS, BRAF, and PIK3CA and upregulation of other receptor tyrosine kinases.** EGFR: Epidermal growth factor receptor; mTOR: Mechanistic target of rapamycin.